Inkjet Printing-Based Immobilization Method for a Single-Step and Homogeneous Competitive Immunoassay in Microchannel Arrays

In this study, we report an inkjet printing-based method for the immobilization of different reactive analytical reagents on a single microchannel for a single-step and homogeneous solution-based competitive immunoassay. The immunoassay microdevice is composed of a poly(dimethylsiloxane) microchannel that is patterned using inkjet printing by two types of reactive reagents as dissolvable spots, namely, antibody-immobilized graphene oxide and a fluorescently labeled antigen. Since nanoliter-sized droplets of the reagents could be accurately and position-selectively spotted on the microchannel, different reactive reagents were simultaneously immobilized onto the same microchannel, which was difficult to achieve in previously reported capillary-based single-step bioassay devices. In the present study, the positions of the reagent spots and amount of reagent matrix were investigated to demonstrate the stable and reproducible immobilization and a uniform dissolution. Finally, a preliminary application to a single-step immunoassay of C-reactive protein was demonstrated as a proof of concept.

Download Full-text

Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis

Arthritis Research & Therapy ◽

10.1186/s13075-015-0578-5 ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 8

Author(s):

Marshelle S Warren ◽

Steven G Hughes ◽

Walter Singleton ◽

Mason Yamashita ◽

Mark C Genovese

Keyword(s):

Rheumatoid Arthritis ◽

Randomized Trial ◽

Antisense Oligonucleotide ◽

Second Generation ◽

High Sensitivity ◽

Proof Of Concept ◽

C Reactive Protein ◽

Double Blind ◽

Reactive Protein ◽

Hs Crp

Download Full-text

ANTIBODY CONJUGATES WITH GOLD NANOPARTICLES AS A COMPONENT OF IMMUNOCHROMATOGRAPHIC DIAGNOSTICUMS: THE INFLUENCE OF SYNTHESIS CONDITIONS ON THE COMPOSITION AND REACTIVITY

BIOTECHNOLOGY: STATE OF THE ART AND PERSPECTIVES ◽

10.37747/2312-640x-2020-18-180-181 ◽

2020 ◽

pp. 180-181

Author(s):

N. Byzova ◽

A. Zherdev ◽

B. Dzantiev

Keyword(s):

Gold Nanoparticles ◽

Immunochromatographic Test ◽

C Reactive Protein ◽

Synthesis Conditions ◽

Reactive Protein ◽

Test Systems ◽

Antibody Conjugates ◽

Analytical Reagents ◽

D Dimer

A series of preparations of gold nanoparticles with diameters from 13 to 60 nm and their conjugates with antibodies (murine immunoglobulins of class G) of different composition were obtained. The composition of the conjugates and the amount of antibodies that retain their reactivity in an immobilized form are characterized. Using the example of immunochromatographic test systems for the detection of D-dimer and C-reactive protein, the effectiveness of conjugates as analytical reagents is compared.

Download Full-text

Elevated high-sensitivity C-reactive protein after percutaneous coronary intervention in patients with stable coronary artery disease: A proof-of-concept study

Research in Cardiovascular Medicine ◽

10.4103/rcm.rcm_14_18 ◽

2018 ◽

Vol 7 (3) ◽

pp. 130

Author(s):

Ahmed Bendary ◽

Bassel Wagdy ◽

TarekAboul Azm ◽

Osama Sanad

Keyword(s):

Coronary Artery Disease ◽

Percutaneous Coronary Intervention ◽

Stable Coronary Artery Disease ◽

High Sensitivity ◽

Coronary Intervention ◽

Proof Of Concept ◽

C Reactive Protein ◽

Reactive Protein ◽

Percutaneous Coronary ◽

Artery Disease

Download Full-text

Single-step purification of rat C-reactive protein and generation of monospecific C-reactive protein antibody

Journal of Chromatography A ◽

10.1016/s0021-9673(00)90413-8 ◽

1988 ◽

Vol 437 ◽

pp. 399-410 ◽

Cited By ~ 4

Author(s):

Donald J. Pruden ◽

Kevin M. Connolly ◽

Vera J. Stecher

Keyword(s):

Single Step ◽

C Reactive Protein ◽

Reactive Protein ◽

Single Step Purification

Download Full-text

Double-Blind Randomised Proof-of-Concept Trial of Canakinumab in Patients with COVID-19 Associated Cardiac Injury and Heightened Inflammation

European Heart Journal Open ◽

10.1093/ehjopen/oeab002 ◽

2021 ◽

Author(s):

Paul C Cremer ◽

Calvin C Sheng ◽

Debasis Sahoo ◽

Siddharth Dugar ◽

Robier Aguillon Prada ◽

...

Keyword(s):

Clinical Improvement ◽

Protein Concentration ◽

Myocardial Injury ◽

Cardiac Injury ◽

Ordinal Scale ◽

High Dose ◽

Proof Of Concept ◽

C Reactive Protein ◽

Double Blind ◽

Reactive Protein

Abstract Aims In COVID-19, myocardial injury is associated with systemic inflammation and higher mortality. Our aim was to perform a proof of concept trial with canakinumab, a monoclonal antibody to IL-1β, in patients with COVID-19, myocardial injury, and heightened inflammation. Methods and Results This trial required hospitalisation due to COVID-19, elevated troponin, and a C reactive protein concentration more than 50 mg/L. The primary endpoint was time to clinical improvement at day 14, defined as either an improvement of two points on a seven category ordinal scale or discharge from the hospital. The secondary endpoint was mortality at day 28. Forty-five patients were randomly assigned to canakinumab 600 mg (n = 15), canakinumab 300 mg (n = 14), or placebo (n = 16). There was no difference in time to clinical improvement compared to placebo (recovery rate ratio (RRR) for canakinumab 600 mg 1.15, 95% confidence interval (CI) 0.46-2.91; RRR for canakinumab 300 mg 0.61, 95% CI 0.23-1.64). At day 28, 3 (18.8%) of 15 patients had died in the placebo group, compared with 3 (21.4%) of 14 patients with 300 mg canakinumab, and 1 (6.7%) of 15 patients with 600 mg canakinumab. There were no treatment-related deaths, and adverse events were similar between groups. Conclusion There was no difference in time to clinical improvement at day 14 in patients treated with canakinumab, and no safety concerns were identified. Future studies could focus on high dose canakinumab in the treatment arm and assess efficacy outcomes at day 28.

Download Full-text